MAIT cells are associated with responsiveness to neoadjuvant immunotherapy in COPD-associated NSCLC
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
BACKGROUND: Patients with non-small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD) experience worse clinical outcomes but respond better to immunotherapy than patients with NSCLC without COPD. Mucosal-associated invariant T (MAIT) cells, a versatile population of innate immune T lymphocytes, have a crucial function in the response to infection and tumors. This study investigated the distribution of MAIT cells in COPD-associated NSCLC and their involvement in the immune response.
METHODS: Flow cytometry, immunohistochemistry, and immunofluorescence were performed on tissue samples of patients with NSCLC, with or without COPD, treated with or without anti-programmed death 1 (PD1) immunotherapy. MAIT cells were stimulated with 5-OP-RU using a mouse subcutaneous tumor model.
RESULTS: Tumors contained significantly more MAIT cells than paraneoplastic tissues, and CD8+ MAIT cells accounted for more than 90% of these cells. Patients with NSCLC and COPD had higher CD8+ MAIT cell counts than those with NSCLC without COPD. Additionally, patients with NSCLC and COPD displayed reduced expression of the activation marker, CD69, and functional markers, granzyme B (GZMB) and interferon γ (IFNγ), and higher expression of the immune exhaustion marker, PD1. Among patients who received immunotherapy, the proportion with a complete or partial response was higher in those with COPD than in those without COPD. In patients with NSCLC and COPD, the major pathologic response (MPR) group had higher MAIT levels than those in the no major pathologic response (NPR) group. In the mouse subcutaneous tumor model stimulation of MAIT cells using 5-OP-RU enhanced the antitumor effects of anti-PD1.
CONCLUSIONS: In patients with NSCLC and COPD, response to immunotherapy is associated with accumulation of CD8+ MAIT cells showing immune exhaustion. These findings may contribute to innovative approaches for immunotherapy targeting CD8+ MAIT cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cancer medicine - 13(2024), 6 vom: 31. März, Seite e7112 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yin, Yanze [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 23.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/cam4.7112 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369993519 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369993519 | ||
| 003 | DE-627 | ||
| 005 | 20240323235605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.7112 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1342.xml |
| 035 | |a (DE-627)NLM369993519 | ||
| 035 | |a (NLM)38509769 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yin, Yanze |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MAIT cells are associated with responsiveness to neoadjuvant immunotherapy in COPD-associated NSCLC |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Patients with non-small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD) experience worse clinical outcomes but respond better to immunotherapy than patients with NSCLC without COPD. Mucosal-associated invariant T (MAIT) cells, a versatile population of innate immune T lymphocytes, have a crucial function in the response to infection and tumors. This study investigated the distribution of MAIT cells in COPD-associated NSCLC and their involvement in the immune response | ||
| 520 | |a METHODS: Flow cytometry, immunohistochemistry, and immunofluorescence were performed on tissue samples of patients with NSCLC, with or without COPD, treated with or without anti-programmed death 1 (PD1) immunotherapy. MAIT cells were stimulated with 5-OP-RU using a mouse subcutaneous tumor model | ||
| 520 | |a RESULTS: Tumors contained significantly more MAIT cells than paraneoplastic tissues, and CD8+ MAIT cells accounted for more than 90% of these cells. Patients with NSCLC and COPD had higher CD8+ MAIT cell counts than those with NSCLC without COPD. Additionally, patients with NSCLC and COPD displayed reduced expression of the activation marker, CD69, and functional markers, granzyme B (GZMB) and interferon γ (IFNγ), and higher expression of the immune exhaustion marker, PD1. Among patients who received immunotherapy, the proportion with a complete or partial response was higher in those with COPD than in those without COPD. In patients with NSCLC and COPD, the major pathologic response (MPR) group had higher MAIT levels than those in the no major pathologic response (NPR) group. In the mouse subcutaneous tumor model stimulation of MAIT cells using 5-OP-RU enhanced the antitumor effects of anti-PD1 | ||
| 520 | |a CONCLUSIONS: In patients with NSCLC and COPD, response to immunotherapy is associated with accumulation of CD8+ MAIT cells showing immune exhaustion. These findings may contribute to innovative approaches for immunotherapy targeting CD8+ MAIT cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a T cell exhaustion | |
| 650 | 4 | |a chronic obstructive pulmonary disease | |
| 650 | 4 | |a immune checkpoint inhibitor therapy | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a mucosal‐associated invariant T cells | |
| 650 | 7 | |a 5-(2-oxopropylideneamino)-6-d-ribitylaminouracil |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Ribitol |2 NLM | |
| 650 | 7 | |a 488-81-3 |2 NLM | |
| 650 | 7 | |a Uracil |2 NLM | |
| 650 | 7 | |a 56HH86ZVCT |2 NLM | |
| 700 | 1 | |a Zeng, Ao |e verfasserin |4 aut | |
| 700 | 1 | |a Abuduwayiti, Abudumijiti |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Zhilong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Keyi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Xinyun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiarui |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Gening |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Jie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g 13(2024), 6 vom: 31. März, Seite e7112 |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:6 |g day:31 |g month:03 |g pages:e7112 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.7112 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 6 |b 31 |c 03 |h e7112 | ||